Paris, Île-de-France, France
32 k abonnés + de 500 relations

Devenir membre pour voir le profil
Ecole Centrale Paris / Université Paris IX Dauphine / CNAM / Mini MBA McKinsey

À propos

IMPORTANT: Opinions and comments are my own
Manuel Gea is a serial entrepreneur…

Articles de Manuel

See all articles

Activité

32 k abonnés

See all activities

Expérience et formation

  • Bio-Modeling Systems

Voir toute l’expérience de Manuel

Découvrez son poste, son ancienneté et plus encore.

ou

En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.

Publications

  • Autism Spectrum Disorders pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment considerations.

    Frontiers in Neuroscience

    We are proud to announce the publication of the world's first integrative neurodevelopmental model describing the mechanisms and dynamics of ASD pathogenesis from pregnancy to child early life: "Autism Spectrum Disorders pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment considerations". the latest output of the "GEMMA (Autism & microbiota) H2020 program" launched in 2019.
    This is the 2nd in a series of 4 publications with Harvard Medical School. The first…

    We are proud to announce the publication of the world's first integrative neurodevelopmental model describing the mechanisms and dynamics of ASD pathogenesis from pregnancy to child early life: "Autism Spectrum Disorders pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment considerations". the latest output of the "GEMMA (Autism & microbiota) H2020 program" launched in 2019.
    This is the 2nd in a series of 4 publications with Harvard Medical School. The first presented a novel mechanistic hypothesis on the interaction between the microbiome and the host in ASD affected individuals: "Autonomic Nervous System Neuroanatomical Alterations Could Provoke and Maintain Gastrointestinal Dysbiosis in Autism Spectrum Disorder (ASD): A Novel Microbiome–Host Interaction Mechanistic Hypothesis". The third will further explain the relative weight of epigenetics and RNA editing mechanisms in the development of ASD, while the fourth will conclude the overall neurodevelopmental model.

    Autres auteurs
    Voir la publication

  • Computational Biophysics of the Skin

    Pan Stanford Publishing

    Features
    • Covers, for the first time, state-of-the-art research in numerical modeling of some skin properties and functions
    • Gathers numerical models from the molecular scale to the tissular scale, as well as some multiscale models and even prospective works based on the systems biology approach
    • Presents numerical models related to availability of data as far as possible
    • Contains an extensive bibliography associated with each chapter

    Summary
    Taking advantage of the…

    Features
    • Covers, for the first time, state-of-the-art research in numerical modeling of some skin properties and functions
    • Gathers numerical models from the molecular scale to the tissular scale, as well as some multiscale models and even prospective works based on the systems biology approach
    • Presents numerical models related to availability of data as far as possible
    • Contains an extensive bibliography associated with each chapter

    Summary
    Taking advantage of the accessibility of the skin in vivo, non-invasive methods were developed about 40 years ago, which have now developed as accurate sources to measure skin properties and structures at the microscopic and macroscopic levels. However, even at the dawn of the twenty-first century, the mechanisms involved in these properties are still only partly understood. As in many domains, including biomedical engineering, numerical modeling has appeared as a complementary key actor for improving our knowledge on skin physiology.
    This book gathers, for the first time, chapters describing scientific computing and numerical modeling for a deeper understanding of mechanisms involved in skin physiology. The book is structured around some skin properties and functions, including optical and biomechanical properties, skin barrier function, and homeostasis, covered through several chapters describing either biological or physical models at different scales.

    http://www.crcpress.com/product/isbn/9789814463843

    Autres auteurs
    Voir la publication

  • La modélisation heuristique au service de la recherche biomédicale

    Biotech & Finances

    L’utilisation de modèles informatiques heuristiques, basés sur l’intuition et l’expérience, permettrait de lever certains des verrous scientifiques qui ralentissent l’avancée de la recherche et la mise sur le marché de médicaments innovants. C’est l’idée que défendent les cinq fondateurs de la société francilienne BMSystems qui développe la plate-forme de modélisation CADITM (computer assisted deductive integration). Celle-ci, mise au point en 2002, n’utilise pas d’algorithmes mathématiques…

    L’utilisation de modèles informatiques heuristiques, basés sur l’intuition et l’expérience, permettrait de lever certains des verrous scientifiques qui ralentissent l’avancée de la recherche et la mise sur le marché de médicaments innovants. C’est l’idée que défendent les cinq fondateurs de la société francilienne BMSystems qui développe la plate-forme de modélisation CADITM (computer assisted deductive integration). Celle-ci, mise au point en 2002, n’utilise pas d’algorithmes mathématiques mais s’appuie sur le travail de biologistes intégrateurs assistés d’outils informatiques, suivant une approche heuristique.

    Voir la publication

  • Biomarkers for Psychiatric Disorders

    Springer

    Biomarkers for Psychiatric Disorders. A collective reference book (Ref. ISBN: 978-0-387-79250-7, November 2008). BMsystems' team with Dr. Francois Iris, CSO of the company, is the author of the integrative biology chapter of the Book.
    The editor, Christoph W. Turck, is head of the Proteomics and Biomarkers branch at the Max Planck Institute of Psychiatry and holds faculty appointments in the Department of Biochemistry at Ludwig Maximilians University Munich and the International Max Planck…

    Biomarkers for Psychiatric Disorders. A collective reference book (Ref. ISBN: 978-0-387-79250-7, November 2008). BMsystems' team with Dr. Francois Iris, CSO of the company, is the author of the integrative biology chapter of the Book.
    The editor, Christoph W. Turck, is head of the Proteomics and Biomarkers branch at the Max Planck Institute of Psychiatry and holds faculty appointments in the Department of Biochemistry at Ludwig Maximilians University Munich and the International Max Planck Research School for Molecular and Cellular Life Sciences

    Autres auteurs
    Voir la publication

  • Integrative biology in the discovery of relevant biomarkers monitoring cognitive disorders pathogenesis and progression

    BioTribune Springer

    Abstract: Cognitive disorders are highly heterogeneous in terms of symptoms, clinical aetiologies, disease progression and thera- peutic responses. Furthermore, their potential biological causes remain largely unknown. Progress at these different levels is cur- rently mired in a vicious circle. The identification of coherent bio- markers, essential for clinical and therapeutic progress, requires an understanding of either the relevant pathogenic processes or, at the very least, of the…

    Abstract: Cognitive disorders are highly heterogeneous in terms of symptoms, clinical aetiologies, disease progression and thera- peutic responses. Furthermore, their potential biological causes remain largely unknown. Progress at these different levels is cur- rently mired in a vicious circle. The identification of coherent bio- markers, essential for clinical and therapeutic progress, requires an understanding of either the relevant pathogenic processes or, at the very least, of the parameters that need to be monitored. But, syndrome-dominated conceptual thinking has become a barrier to understanding the biological processes linked to diseases characterized by clinical and therapeutic heterogeneity. As a result, current biomarkers of cognitive disorders are much too numerous, too heterogeneous and too variable to serve useful purposes. This leads to an untenable situation that precludes coherent therapeutic developments since it effectively prevents defining what could constitute valid biological, clinical and therapeutic approaches. How to escape from this situation? The problem could be partly resolved by adopting the much wider views allowed by “system-wide” approaches: indeed, by constructing predictive theoretical models of what could constitute pathological cognitive processes.
    This, naturally, shall require the integration of massive amounts of highly heterogeneous and often conflicting information. The following article aims to provide a necessarily brief overview of the concepts, the breadth of data and the variety of network dynamics that will have to be considered while proposing a functional model- building approach, experimentally validated in vitro and in vivo,
    that could be fruitfully utilised.

    Autres auteurs
    Voir la publication

Cours

  • Business models

    -

  • Business models impact of social and education context

    -

  • Economy

    -

  • General Semantics

    -

  • Information Technologies

    -

  • Life sicences

    -

  • Management of innovation

    5

  • Operational research

    -

  • Sociology of organizations

    -

  • Supply chain management

    -

Projets

  • GEMMA H2020 program (Autism & Microbiota)

    WORLD AUTISM AWARENESS DAY 2024: To help clinicians and parents to better care for ASD patients, H2020 GEMMA European consortium members publish the world's first integrative model of ASD development GUIDE, outlining the mechanisms and dynamics of ASD pathogenesis from pregnancy to early childhood.

    The first paper presents a novel mechanistic hypothesis on the interaction between the patient and its
    microbiome in ASD affected individuals: "Autonomic Nervous System Neuroanatomical…

    WORLD AUTISM AWARENESS DAY 2024: To help clinicians and parents to better care for ASD patients, H2020 GEMMA European consortium members publish the world's first integrative model of ASD development GUIDE, outlining the mechanisms and dynamics of ASD pathogenesis from pregnancy to early childhood.

    The first paper presents a novel mechanistic hypothesis on the interaction between the patient and its
    microbiome in ASD affected individuals: "Autonomic Nervous System Neuroanatomical Alterations Could
    Provoke and Maintain Gastrointestinal Dysbiosis in Autism Spectrum Disorder (ASD): A Novel Microbiome–
    Host Interaction Mechanistic Hypothesis" (download pdf open access).
    The second article presents the integrative neurodevelopmental model thta describes the mechanisms
    and dynamics of ASD pathogenesis from pregnancy to early childhood: "Autism Spectrum Disorders
    pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment
    considerations"(download pdf open access),
    The third paper unravels the impact of epitranscriptomics in ASD pathogenesis by explaning how abrupt
    changes in environmental conditions in utero, such as those conferred by maternal inflammation/immune
    activation, influence RNA editing mechanisms, with the combination of these processes altering fetal
    brain development and leading to ASD phenotypes. “RNA epitranscriptomics dysregulation: A major
    determinant for significantly increased risk of ASD pathogenesis” (download pdf open access).

  • FIBROMYALGIA & FACIAL PAIN NOVEL THERAPIES DISCOVERY

    - aujourd’hui

    Bio-Modeling Systems (BMSystems) and
    Aepodia have decided to combine their respective competences. Conscious of the urgent needs to significantly improve and accelerate knowledge and treatments in the realm of specific pains, where the challenges areconsiderable and therapeutic responses non satisfactory, the partners have launched an innovative research program which combines the scientific, combined products development and clinical know-how of the research mathematical (CADI™) modeling…

    Bio-Modeling Systems (BMSystems) and
    Aepodia have decided to combine their respective competences. Conscious of the urgent needs to significantly improve and accelerate knowledge and treatments in the realm of specific pains, where the challenges areconsiderable and therapeutic responses non satisfactory, the partners have launched an innovative research program which combines the scientific, combined products development and clinical know-how of the research mathematical (CADI™) modeling and scientific talents of BMSystems’ team of biologists. More specifically, Bio-Modeling Systems and Aepodia have started to construct two new CADI™ models that describe and explain the Fibromyalgia and chronic facial pain mechanisms. The purpose of this collaboration is to open new avenues that will be decisive for the understanding, the diagnosis and the treatment of severe pains. The A1 phase of this program is entirely self-financed by the partners, revealing their confidence in their capacity to jointly identify and characterize mechanisms that will lead quicker to specific combined therapies to the patients.

    Autres créateurs
    Voir le projet

  • Eliminate as much as possible the Use of Animals in Contact Allergy Testing for cosmetic products

    Context
    May 2013, the European Unions bans the import and sale of cosmetics containing ingredients tested on animals.

    Objective of the program:
    Offer to the industry a highly effective, competitive and reliable alternative to detect & characterize the potential for irritant contact dermatitis and/or allergic contact dermatitis complex formulations could have in normal skin in vivo, using reconstructed skin, in-vitro and in-silico tools.
    Provide possible “contact allergy free”…

    Context
    May 2013, the European Unions bans the import and sale of cosmetics containing ingredients tested on animals.

    Objective of the program:
    Offer to the industry a highly effective, competitive and reliable alternative to detect & characterize the potential for irritant contact dermatitis and/or allergic contact dermatitis complex formulations could have in normal skin in vivo, using reconstructed skin, in-vitro and in-silico tools.
    Provide possible “contact allergy free” formulation strategy combining interesting allergic products with their corresponding inhibitors to develop innovative formulas.
    Develop a range of products/services to fit clients’ needs.
    R&D Partners: Open for complementary partners (research, industry, etc.…)

    Work completed under progress or to be done:
    CADI™ model under construction.
    Identification of the parameters characterizing pathway-specific & cross-talk inductions.
    Construction of the complementary mathematical in-silico model.
    Identification of appropriate program validation tests.
    Development of the future tools and software to run and exploit the tests.
    Contact Allergy Testing solution evaluation by Cosmetics partners.

    Autres créateurs
    Voir le projet

  • PSYCHIATRIC IMMUNO-INFLAMMATORY RESEARCH PROGRAM

    - aujourd’hui

    Bio-Modeling Systems and the Foundation FondaMental join forces to decipher the immuno-inflammatory mechanisms that could give rise to psychiatric diseases, such as bipolar disorders and schizophrenia, and thus open novel therapeutic avenues.

    Bio-Modeling Systems (BMSystems) and the Foundation for Scientific Cooperation FondaMental have decided to merge their respective competences. Conscious of the urgent needs to significantly improve knowledge and treatments in the realm of…

    Bio-Modeling Systems and the Foundation FondaMental join forces to decipher the immuno-inflammatory mechanisms that could give rise to psychiatric diseases, such as bipolar disorders and schizophrenia, and thus open novel therapeutic avenues.

    Bio-Modeling Systems (BMSystems) and the Foundation for Scientific Cooperation FondaMental have decided to merge their respective competences. Conscious of the urgent needs to significantly improve knowledge and treatments in the realm of psychiatry, where the challenges are considerable and therapeutic responses non satisfactory, the partners have launched an innovative research program which combines the scientific and clinical know-how of the research teams attached to the foundation FondaMental and the heuristic, non-mathematical (CADI™*) modeling talents of BMSystems’ team of biologists.

    More specifically, Bio-Modeling Systems and the Foundation FondaMental aim to construct a new CADI™ model that describes and explains the immuno inflammatory mechanisms that can underlie the pathogenesis and clinical progression of bipolar disorders and schizophrenia. The purpose of this collaboration is to open new avenues that will be decisive for the understanding, the diagnosis and the treatment of severe psychiatric disorders. The A1 phase of this program is entirely self-financed by the partners, revealing their confidence in their capacity to jointly identify and characterize mechanisms that will allow adapting treatments to the physiopathological profiles of patients. The scientific program is placed under the shared leadership of Pr. Marion Leboyer, director of the Foundation FondaMental, and Dr. François Iris, scientific director of Bio-Modeling Systems.

    Autres créateurs
    Voir le projet

  • CHRONIC ANXIETY MECHANISMS RESEARCH PROGRAM

    On-going self-funded European collaborative research program addressing the identification of biomarkers attached to chronic anxiety.
    FIRST publication: http://www.bmsystems.net/download/publication-BMSystems-Max-Planck-Munich-anxiety-associated-mechanisms-in-cingulate-cortex-synapes-2014.pdf

    The first scientific results have been obtained and will be formally presented in May, at the 9th International Workshop on Computational Neuropsychiatry in Munich.

    * 2014:CNS Psychiatry…

    On-going self-funded European collaborative research program addressing the identification of biomarkers attached to chronic anxiety.
    FIRST publication: http://www.bmsystems.net/download/publication-BMSystems-Max-Planck-Munich-anxiety-associated-mechanisms-in-cingulate-cortex-synapes-2014.pdf

    The first scientific results have been obtained and will be formally presented in May, at the 9th International Workshop on Computational Neuropsychiatry in Munich.

    * 2014:CNS Psychiatry publication: American Journal of Psychiatry and Neuroscience. Second publications with Max Planck Institute of Psychiatry in Munich: Differential proteomics analyses reveal anxiety-associated molecular and cellular mechanisms in cingulate cortex. The first output of the DECIUS CNS research program. synapses.
    http://www.bmsystems.net/download/publication-BMSystems-Max-Planck-Munich-anxiety-associated-mechanisms-in-cingulate-cortex-synapes-2014.pdf

    Autres créateurs
    Voir le projet

  • PARKINSON'S DISEASE NOVEL THERAPY

    Domain: Parkinson’s disease. Collaborative CADI™ program
    Context: Numerous attempts to utilize low-toxicity metabolic co-factors have been made over the years but all have proven ineffective.

    Objective: Build a CADI™ model that describes the mechanisms which:
    1-could give rise to mitochondrial dysfunctions that would
    2-most severely affect dopaminergic neurons.

    Work done or to be done:
    The IDUNN program led to a combinatorial therapeutic approach* utilizing two…

    Domain: Parkinson’s disease. Collaborative CADI™ program
    Context: Numerous attempts to utilize low-toxicity metabolic co-factors have been made over the years but all have proven ineffective.

    Objective: Build a CADI™ model that describes the mechanisms which:
    1-could give rise to mitochondrial dysfunctions that would
    2-most severely affect dopaminergic neurons.

    Work done or to be done:
    The IDUNN program led to a combinatorial therapeutic approach* utilizing two molecules that had long been on the market, neither of which has any known toxicity or undesirable effects.
    This potential treatment was exposed, under strict confidentiality, to the criticism of internationally respected clinical specialists. It received their full approval.
    Implementation of the clinical proof of concept upon Parkinson’s disease patients is currently under negotiation.

    Autres créateurs
    Voir le projet

  • BMSystems' Mechanisms-Based Medicine global presentation

    - aujourd’hui

    Understanding the mechanisms of a disease becomes the key objective.To implement Mechanisms-Based Medicine, we invented:
    - a systems biology approach that address the life sciences’ issues
    - a revised discovery process that address complex diseases issues
    - a novel continuum between e R&D and e Health in a global digital health strategy.
    Proposed Global therapies discovery & validation process:
    DISEASE: Describe the physiopathology of the disease with clinicians and patients…

    Understanding the mechanisms of a disease becomes the key objective.To implement Mechanisms-Based Medicine, we invented:
    - a systems biology approach that address the life sciences’ issues
    - a revised discovery process that address complex diseases issues
    - a novel continuum between e R&D and e Health in a global digital health strategy.
    Proposed Global therapies discovery & validation process:
    DISEASE: Describe the physiopathology of the disease with clinicians and patients feedback.
    MECHANISMS: Discovery of the causal and symptomatic Mechanisms of the disease.
    BIOMARKERS: Identify relevant biomarkers or specific combination of biomarkers that could measure de mechanisms deregulations at different stages of the disease.
    TARGETS: based on the mechanisms, Identify what could be the best targets to specifically address the causative deregulations.
    SOLUTIONS: We “play” with the mechanisms. Propose a diagnostic and therapeutic strategy to address the relevant mechanisms deregulations with existing drugs or novel drugs with the necessary delivery systems and therapies follow-up.
    FEED BACK LOOP: Integrate the results from e R&D or e Health experimentations into the validation process to improve the global patient and disease follow-up.

    Autres créateurs
    Voir le projet

Langues

  • English

    Capacité professionnelle complète

  • French

    Capacité professionnelle complète

Voir le profil complet de Manuel

  • Découvrir vos relations en commun
  • Être mis en relation
  • Contacter Manuel directement
Devenir membre pour voir le profil complet

Autres profils similaires

Découvrir plus de posts

Ajoutez de nouvelles compétences en suivant ces cours

Voir tous les cours